Colchicine, an anti-rheumatic agent, as a potential compound for the treatment of COVID-19
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has swept the world in a pandemic. The disease (COVID-19) is characterized by acute respiratory distress, and there is an immediate need for any effective agent before the development of a vaccine. Coronavirus-19 disease (C...
Saved in:
Main Authors: | Carlo Perricone, Elena Bartoloni, Roberto Gerli |
---|---|
Format: | article |
Language: | EN |
Published: |
Termedia Publishing House
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/05c69d9bf924417f96de790ea9f6910c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of colchicine on mortality in patients with COVID-19: A meta-analysis
by: Dimitrios A. Vrachatis, et al.
Published: (2021) -
COVID-19 – rheumatic diseases and rheumatologists
by: Maria Maślińska
Published: (2021) -
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine
by: Dimitrios A. Vrachatis, et al.
Published: (2021) -
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity
by: Marilia Barreca, et al.
Published: (2021) -
Update on COVID-19 vaccines and autoimmune-mediated rheumatic diseases
by: Lakshmanan Suresh
Published: (2021)